-
Mashup Score: 6
Introduction: The association of acute lymphoblastic leukaemia (ALL) and cystic fibrosis (CF) is rare. We present the case of a paediatric patient affected by C…
Source: journals.sagepub.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 18
This review examines the incidence of second primary cancers after treatment with chimeric antigen receptor T cells in patients with hematologic cancers.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet-
@JAMAOnc https://t.co/5HmtLpyqBA Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy
-
-
Mashup Score: 6Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia - 1 month(s) ago
Key Points. Inati-cel can induce high and durable responses in r/r B-ALL patients with best ORR achieving 85.4% and median DOR being 20.7 months.At the med
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia https://t.co/tSfeZa1Wlt
-
-
Mashup Score: 8Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy - 1 month(s) ago
Key Points. Early flow-based MRD dynamics are independently associated with RFS in patients with AML undergoing frontline therapyPatients with intermediate
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy https://t.co/AdT8kvsSUO
-
-
Mashup Score: 22Dual targeting CAR-T cells for B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma - 1 month(s) ago
Relapse after CD19-directed chimeric antigen receptor (CAR)-T cell therapy remains a major challenge in B-cell acute lymphoblastic leukaemia (ALL) and B-ce
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Dual targeting CAR-T cells for B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma https://t.co/zbMlt1mJUM
-
-
Mashup Score: 6Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia - 1 month(s) ago
Key Points. Inati-cel can induce high and durable responses in r/r B-ALL patients with best ORR achieving 85.4% and median DOR being 20.7 months.At the med
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia https://t.co/tSfeZa1Wlt
-
-
Mashup Score: 9Venetoclax plus low intensity chemotherapy for adults with acute lymphoblastic leukemia - 1 month(s) ago
Key Points. Venetoclax plus low intensity chemotherapy can be safely administered in acute lymphoblastic leukemia (ALL).Venetoclax plus low intensity chemo
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Venetoclax plus low intensity chemotherapy for adults with acute lymphoblastic leukemia https://t.co/ZSTZ0vxBlB
-
-
Mashup Score: 7Model-based dosing for better survival after transplantation - 1 month(s) ago
In this issue of Blood Advances, Dvorak et al1 enhanced our understanding of the impact of rabbit antithymocyte globulin (rATG) exposure on outcomes after
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Model-based dosing for better survival after transplantation https://t.co/JCLpZ4Puew
-
-
Mashup Score: 1COMPARABLE OUTCOMES AFTER BUSULFAN- OR TREOSULFAN-BASED CONDITIONING FOR ALLO-HSCT IN CHILDREN WITH ALL-RESULTS OF FORUM - 1 month(s) ago
Key Points. Chemo conditioning with busulfan- or treosulfan-based regimens yields comparable outcomes for allo-HSCT in children with ALL.Either regimen can
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
COMPARABLE OUTCOMES AFTER BUSULFAN- OR TREOSULFAN-BASED CONDITIONING FOR ALLO-HSCT IN CHILDREN WITH ALL-RESULTS OF FORUM https://t.co/FYfE2xpyuY
-
-
Mashup Score: 24Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML - 1 month(s) ago
The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recentl
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML https://t.co/xeKUmm8sFc
-
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis - https://t.co/8UQgT1oLAy